medical affairs teams

By Elio Evangelista, Director of Research As two of the major roles of medical science liaisons (MSLs), identifying influential physicians and building relationships with those thought leaders occupy more time than other activities. The actual amount...

By David Richardson, Research Team Leader The Office of the Inspector General at Health and Human Services (OIG) has been highly focused recently on tracking and publicizing pharmaceutical companies' payments to thought leader physicians and clinical...

By David Richardson, Research Team Leader Post-marketing research is a growth area. An ever more cautious and stringent regulatory environment, payers that require more and more data to justify formulary approval and reimbursement, and more crowded...

By Stephanie Swanson, Strategic Marketing Manager The CEI research team is launching two new benchmarking studies that will explore the value proposition, Return-on-Investment and performance measurement of the Medical Science Liaison function. Early...

Cutting Edge Information's new customizable "MSL Data Suite" combines the company's experience in researching medical science liaison performance and MSL program management with our team's strength in providing Life Science companies with benchmarking data, analysis...

By Ryan McGuire, Senior Research Analyst Pharmaceutical companies are growing more strategic in their investigator initiated trial (IIT) selection. As Research and Development organizations have sharpened their focus on mission-critical pre-approval...

This is the first blog entry in a two-part series on journal selection. By Ryan McGuire,Senior Research Analyst Evaluating the medical journal landscape is the first step toward making sure manuscripts find their way to the appropriate home. In fact,...

Our current review of pharmaceutical and biotechnology strategy for the new year finds that 42 percent of companies will be increasing their budgets for investigator initiated trials. Companies fund investigator initiate trials (IITs) to support additional clinical...

Country-level medical affairs budgets currently average $1.9 million across Asia, Europe, North America and South America, according to our recent benchmarking study, with pharmaceutical and biotech companies boosting their investment in medical affairs affiliates...

By Elio Evangelista,Director of Research In about five weeks, pharmaceutical, biotechnology and medical device companies will have to start compiling and aggregating data on their physician expenditures to meet the requirements spelled out in the Physician...